| BE0392-1MG
| InVivoMAb anti-mouse myeloperoxidase (MPO)
| 1 mg
| BioXCell
| in vivo administration, in vitro administration, I
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BP0058-5MG
| InVivoPlus anti-mouse TNF?
| 5 mg
| BioXCell
| in vivo TNF? neutralization, in vitro TNF? neutral
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0402-5MG
| InVivoMAb anti-human GPC-2
| 5 mg
| BioXCell
| , ,
|
| Mouse
|
| Request Quotation
| Request
|
| BE0396-50MG
| InVivoMAb anti-human/mouse GRP78
| 50 mg
| BioXCell
| in vivo GRP78 blockade, in vitro GRP78 blockade, W
|
| Mouse
| Human, Mouse
| Request Quotation
| Request
|
| BP0090-25MG
| InVivoPlus rat IgG2b isotype control, anti-keyhole limpet hemocyanin
| 25 mg
| BioXCell
|
|
| Rat
|
| Request Quotation
| Request
|
| BP0086-5MG
| InVivoPlus mouse IgG2b isotype control, unknown specificity
| 5 mg
| BioXCell
|
|
| Mouse
|
| Request Quotation
| Request
|
| BP0310-25MG
| InVivoPlus anti-mouse VISTA
| 25 mg
| BioXCell
| in vivo blocking of VISTA signaling, in vitro bloc
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BP0175-50MG
| InVivoPlus anti-mouse CD71 (TfR1)
| 50 mg
| BioXCell
| in vivo depletion of CD71+ cells
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0012-25MG
| InVivoPlus anti-mouse CD25 (IL-2R?)
| 25 mg
| BioXCell
| in vivo regulatory T cell depletion, Flow cytometr
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0274-50MG
| InVivoPlus anti-mouse TIGIT
| 50 mg
| BioXCell
| in vivo TIGIT stimulation, Flow cytometry
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0387-100MG
| InVivoMAb anti-mouse/human phosphorylated PD-1 (CD279)
| 100 mg
| BioXCell
| Western Blot, Flow Cytometry
|
| Mouse
| Human, Mouse
| Request Quotation
| Request
|
| BP0033-2-100MG
| InVivoPlus anti-mouse PD-1 (CD279)
| 100 mg
| BioXCell
| in vivo blocking of PD-1/PD-L signaling, in vitro
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BP0091-25MG
| InVivoPlus polyclonal Armenian hamster IgG
| 25 mg
| BioXCell
|
|
| Armenian Hamster
|
| Request Quotation
| Request
|
| BP0164-5MG
| InVivoPlus anti-mouse CTLA-4 (CD152)
| 5 mg
| BioXCell
| in vivo CTLA-4 neutralization, Western blot
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0383-50MG
| InVivoMAb anti-mouse/human/rat PD-L1
| 50 mg
| BioXCell
| in vivo PD-L1 blockade
, in vitro PD-L1 blockade
,
|
| Mouse/Human/Rat
|
| Request Quotation
| Request
|
| BP0169-100MG
| InVivoPlus anti-mouse 4-1BB (CD137)
| 100 mg
| BioXCell
| in vivo activation of 4-1BB
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0146-50MG
| InVivoPlus anti-mouse PD-1 (CD279)
| 50 mg
| BioXCell
| in vivo blocking of PD-1/PD-L signaling
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0410-100MG
| InVivoMAb anti-human EphA2
| 100 mg
| BioXCell
|
|
| Mouse
| Human
| Request Quotation
| Request
|
| BP0213-25MG
| InVivoPlus anti-mouse CSF1R (CD115)
| 25 mg
| BioXCell
| in vivo macrophage depletion, in vitro CSF1R neutr
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0410-5MG
| InVivoMAb anti-human EphA2
| 5 mg
| BioXCell
|
|
| Mouse
| Human
| Request Quotation
| Request
|
| BP0089-5MG
| InVivoPlus rat IgG2a isotype control, anti-trinitrophenol
| 5 mg
| BioXCell
|
|
| Rat
|
| Request Quotation
| Request
|
| BE0405-50MG
| InVivoMAb anti-human mesothelin
| 50 mg
| BioXCell
| , ,
|
| Rabbit
|
| Request Quotation
| Request
|
| BP0173-25MG
| InVivoPlus anti-mouse IL-17A
| 25 mg
| BioXCell
| in vivo IL-17A neutralization
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BP0016-2-25MG
| InVivoPlus anti-mouse CD40
| 25 mg
| BioXCell
| in vivo CD40 activation, in vitro B cell stimulati
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0241-25MG
| InVivoPlus anti-mouse IFNAR-1
| 25 mg
| BioXCell
| in vivo IFNAR-1 blockade, in vitro IFNAR-1 blockad
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BP0239-5MG
| InVivoPlus anti-mouse 4-1BB (CD137)
| 5 mg
| BioXCell
| in vivo 4-1BB stimulation, in vitro 4-1BB stimulat
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0411-100MG
| InVivoMAb anti-human GC1q R (C1QBP)
| 100 mg
| BioXCell
| , ,
|
| Mouse
|
| Request Quotation
| Request
|
| BP0001-1-50MG
| InVivoPlus anti-mouse CD3?
| 50 mg
| BioXCell
| in vivo T cell depletion, in vitro T cell stimulat
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BP0066-50MG
| InVivoPlus anti-mouse Thy1.2 (CD90.2)
| 50 mg
| BioXCell
| in vivo ILC depletion, in vivo T cell depletion, W
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0045-50MG
| InVivoPlus anti-mouse IL-4
| 50 mg
| BioXCell
| in vivo IL-4 neutralization, in vitro IL-4 neutral
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0385-100MG
| InVivoMAb anti-mouse DKK3
| 100 mg
| BioXCell
| in vivo DKK3 blocking, in vitro DKK3 blocking, Wes
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BP0075-1-100MG
| InVivoPlus anti-mouse Ly6G
| 100 mg
| BioXCell
| in vivo neutrophil depletion, in vivo MDSC depleti
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0066-25MG
| InVivoPlus anti-mouse Thy1.2 (CD90.2)
| 25 mg
| BioXCell
| in vivo ILC depletion, in vivo T cell depletion, W
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0297-25MG
| InVivoPlus human IgG1 isotype control
| 25 mg
| BioXCell
|
|
| Human
|
| Request Quotation
| Request
|
| BP0055-100MG
| InVivoPlus anti-mouse IFN?
| 100 mg
| BioXCell
| in vivo IFN? neutralization, in vitro IFN? neutral
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0393-25MG
| InVivoMAb anti-mouse myeloperoxidase (MPO)
| 25 mg
| BioXCell
| in vivo administration, in vitro administration, I
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BP0012-100MG
| InVivoPlus anti-mouse CD25 (IL-2R?)
| 100 mg
| BioXCell
| in vivo regulatory T cell depletion, Flow cytometr
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0051-100MG
| InVivoPlus anti-mouse IL-12 p40
| 100 mg
| BioXCell
| in vivo IL-12p40 neutralization, p40 affinity chro
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BE0405-1MG
| InVivoMAb anti-human mesothelin
| 1 mg
| BioXCell
| , ,
|
| Rabbit
|
| Request Quotation
| Request
|
| BP0033-2-5MG
| InVivoPlus anti-mouse PD-1 (CD279)
| 5 mg
| BioXCell
| in vivo blocking of PD-1/PD-L signaling, in vitro
|
| Armenian Hamster
| Mouse
| Request Quotation
| Request
|
| BE0410-25MG
| InVivoMAb anti-human EphA2
| 25 mg
| BioXCell
|
|
| Mouse
| Human
| Request Quotation
| Request
|
| BE0414-1MG
| InVivoMAb anti-rat TCR ?/?
| 1 mg
| BioXCell
| in vivo ?/? T cell depletion, Flow cytometry
|
| Mouse
| Rat
| Request Quotation
| Request
|
| BP0173-5MG
| InVivoPlus anti-mouse IL-17A
| 5 mg
| BioXCell
| in vivo IL-17A neutralization
|
| Mouse
| Mouse
| Request Quotation
| Request
|
| BE0408-5MG
| InVivoMAb anti-human TROP-2
| 5 mg
| BioXCell
| Western blot, Immunohistochemistry (frozen), Flow
|
| Mouse
| Human
| Request Quotation
| Request
|
| BE0395-5MG
| InVivoMAb anti-mouse/human Mac-2 (Galectin-3)
| 5 mg
| BioXCell
| Western blot, Immunofluorescence, Immunohistochemi
|
| Rat
| Human, Mouse
| Request Quotation
| Request
|
| BP0290-5MG
| InVivoPlus rat IgG1 isotype control, anti-trinitrophenol
| 5 mg
| BioXCell
|
|
| Rat
| Rat
| Request Quotation
| Request
|
| BP0087-25MG
| InVivoPlus polyclonal Syrian hamster IgG
| 25 mg
| BioXCell
|
|
| Syrian Hamster
|
| Request Quotation
| Request
|
| BP0061-100MG
| InVivoPlus anti-mouse CD8?
| 100 mg
| BioXCell
| in vivo CD8+ T cell depletion, Western blot
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0066-100MG
| InVivoPlus anti-mouse Thy1.2 (CD90.2)
| 100 mg
| BioXCell
| in vivo ILC depletion, in vivo T cell depletion, W
|
| Rat
| Mouse
| Request Quotation
| Request
|
| BP0057-50MG
| InVivoPlus anti-mouse/human/rat/monkey/hamster/canine/bovine TGF-?
| 50 mg
| BioXCell
| in vivo TGF? neutralization, in vitro TGF? neutral
|
| Mouse
| Goat, Dog, Hamster, Human, Monkey, Mouse, Rat
| Request Quotation
| Request
|